Hantz Financial Services Inc. Trims Stock Holdings in Roche Holding AG $RHHBY

Hantz Financial Services Inc. decreased its stake in Roche Holding AG (OTCMKTS:RHHBY) by 7.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,696 shares of the company’s stock after selling 2,380 shares during the quarter. Hantz Financial Services Inc.’s holdings in Roche were worth $1,292,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. PNC Financial Services Group Inc. grew its position in shares of Roche by 2.0% during the first quarter. PNC Financial Services Group Inc. now owns 16,234 shares of the company’s stock worth $668,000 after purchasing an additional 323 shares in the last quarter. Confluence Investment Management LLC grew its position in shares of Roche by 5.1% during the second quarter. Confluence Investment Management LLC now owns 15,225 shares of the company’s stock worth $621,000 after purchasing an additional 734 shares in the last quarter. Accent Capital Management LLC purchased a new stake in shares of Roche during the first quarter worth about $35,000. North Star Asset Management Inc. grew its position in shares of Roche by 7.8% during the first quarter. North Star Asset Management Inc. now owns 17,305 shares of the company’s stock worth $712,000 after purchasing an additional 1,255 shares in the last quarter. Finally, S&CO Inc. grew its position in shares of Roche by 4.1% during the first quarter. S&CO Inc. now owns 51,199 shares of the company’s stock worth $2,101,000 after purchasing an additional 2,014 shares in the last quarter.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. HSBC upgraded Roche from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a research report on Thursday, October 2nd. Hsbc Global Res upgraded Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 2nd. Jefferies Financial Group cut Roche from a “hold” rating to a “moderate sell” rating in a research report on Monday, October 27th. Finally, Morgan Stanley reissued an “underweight” rating on shares of Roche in a research note on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $50.00.

Roche Price Performance

Shares of Roche stock opened at $40.40 on Friday. The stock has a 50 day moving average of $42.46 and a 200 day moving average of $40.81. Roche Holding AG has a 12 month low of $34.10 and a 12 month high of $45.94.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.